GLP-1 semaglutide for weight management: the essentials

What exactly does semaglutide do inside the body?

GLP-1 stands for glucagon-like peptide-1, a hormone the gut releases naturally after eating. Semaglutide is a synthetic version of that hormone, engineered to last far longer in the bloodstream than the version your body makes. When it binds to GLP-1 receptors (in the brain's appetite centres, in the stomach, and in the pancreas) the result is a combination of effects: hunger signals quieten, the stomach takes longer to empty, and the sense of fullness arrives sooner and stays longer.

That mechanism matters for weight management because it works with the body's own signalling rather than suppressing appetite through stimulants or blocking fat absorption. It is worth being clear, though, that semaglutide is not a standalone fix. Clinical trials were conducted alongside a reduced-calorie diet and increased physical activity, and that context carries through into how it is licensed and prescribed.

Semaglutide also has a glucose-dependent effect on insulin release, which is why the same molecule appears in medicines for type 2 diabetes. Ozempic and Rybelsus use semaglutide but hold different licences and different dose ranges — neither is licensed for weight management, so they should never be treated as interchangeable with Wegovy. That distinction is covered in more detail on our semaglutide overview page.

Which UK patients does the evidence support?

The STEP 1 trial (a 68-week, placebo-controlled study published in the New England Journal of Medicine) enrolled adults with obesity or overweight plus at least one weight-related condition, none of whom had type 2 diabetes. Participants on semaglutide 2.4 mg lost an average of around 15% of body weight, compared with roughly 2.4% on placebo, both groups following lifestyle guidance.

Those results informed the UK licence. Wegovy is approved for adults with a BMI of 30 or above, or 27 to 29.9 where at least one weight-related condition is present, things like high blood pressure, raised cholesterol, obstructive sleep apnoea or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, reflecting differences in metabolic risk at lower body weights.

A prescriber looks at the whole picture, not the BMI in isolation. Certain conditions make semaglutide unsuitable: a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, and some other gastrointestinal conditions all require careful prescriber consideration. Pregnancy, breastfeeding, trying to conceive, and anyone under 18 sit outside the licence entirely. If you want to understand how semaglutide interacts with specific conditions like psoriatic arthritis, that deserves its own clinical conversation.

What does a typical semaglutide treatment pathway look like?

Wegovy injections start at 0.25 mg once weekly and are increased in stages (roughly every four weeks) through 0.5 mg, 1.0 mg, and 1.7 mg, reaching the standard 2.4 mg maintenance dose. In April 2026 the MHRA approved a 7.2 mg maintenance option, supplied as a dedicated single-dose pen, for adults with a BMI of 30 or above. That higher dose is not automatically offered; it follows clinical review of progress at lower doses.

The oral tablet version, approved in June 2026, follows a different schedule: once daily, beginning at 1.5 mg and escalating through 4 mg and 9 mg to a 25 mg maintenance dose, with a minimum of one month at each level. It is taken first thing in the morning on an empty stomach with a small amount of plain water, and nothing else (food, coffee, other medicines) for at least 30 minutes afterwards. No refrigeration is needed, which matters for anyone whose schedule makes cold-chain storage awkward. If you order treatment on a Monday before noon and it is clinically approved, it is dispatched the same day and arrives free the next working day; keeping that rhythm in mind makes the 30-minute morning window easier to plan around.

Our Wegovy treatment page sets out both delivery formats and what the consultation process covers. For a sense of what private treatment currently costs, the Wegovy pricing page is the clearest starting point.

How does GLP-1 semaglutide fit into NHS and private access in the UK?

NICE recommended Wegovy (semaglutide) for NHS use in March 2023 under Technology Appraisal 875, but with specific conditions: it can be prescribed for a maximum of two years, only within a specialist weight management service offering multidisciplinary support, and for adults meeting defined BMI and comorbidity thresholds. In practice, NHS waiting lists for specialist weight management services are often lengthy, and not everyone meets the criteria as currently applied.

Private prescription is the alternative. A regulated online pharmacy (one you can check on the GPhC pharmacy register) can offer a consultation, a same-day clinical review by a registered Independent Prescriber, and dispatch once approval is confirmed. That route does not require a GP referral and carries no waiting list, though clinical suitability still governs every decision. At nume, every consultation is read by a prescriber, not automated software, before anything is dispensed. If you are starting out on the treatment journey, our guides to semaglutide 1 and semaglutide 2 walk through the dose stages in detail, which can help you know what to expect before your first consultation.

If you are ready to see whether semaglutide GLP-1 treatment is appropriate for you, checking your eligibility through a free consultation is the right first step. There is no obligation, and the clinical review happens the same day.